International Stem Cell Corporation Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC
CARLSBAD, CA--(Marketwired - March 07, 2016) - International Stem Cell Corporation (OTCQB: ISCO), a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it is enrolling patients in the Phase I trial of ISC- …